Hikma Pharmaceuticals’ (HIK) “Underweight” Rating Reiterated at Barclays
A number of other analysts also recently weighed in on the company. Citigroup increased their price objective on Hikma Pharmaceuticals from GBX 1,675 ($21.82) to GBX 2,100 ($27.35) and gave the company a buy rating in a report on Monday, August 20th. Peel Hunt restated a hold rating on shares of Hikma Pharmaceuticals in a report on Thursday, May 31st. JPMorgan Chase & Co. restated a neutral rating and issued a GBX 1,050 ($13.68) price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, August 21st. Finally, Numis Securities restated a hold rating on shares of Hikma Pharmaceuticals in a report on Wednesday, August 15th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of GBX 1,330.22 ($17.33).
LON HIK opened at GBX 1,879 ($24.48) on Monday. Hikma Pharmaceuticals has a twelve month low of GBX 814.20 ($10.61) and a twelve month high of GBX 2,346 ($30.56).
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.